前列腺癌
恶性肿瘤
泌尿生殖系统
疾病
医学
微生物群
癌症
免疫系统
癌变
前列腺
免疫学
内科学
生物信息学
肿瘤科
生物
作者
Alessandro Rizzo,Matteo Santoni,Veronica Mollica,Michelangelo Fiorentino,Giovanni Brandi,Francesco Massari
标识
DOI:10.1016/j.semcancer.2021.09.007
摘要
Prostate cancer remains the most frequently diagnosed non-skin malignancy in male patients, still representing one of the main causes of cancer-related death worldwide. Evidence is mounting that suggests the putative role of microbiota in the carcinogenesis as well as in modulating the efficacy and activity of anticancer treatments (e.g., chemotherapy, immune checkpoint inhibitors, targeted therapies) in a large number of hematological and solid tumors. However, few data are available regarding the interactions between prostate cancer and microbiome so far, in particular in terms of the impact of microbiota on disease development, pathogenesis, and response to medical treatments in this genitourinary malignancy. Herein, we provide an overview of current knowledge, novel insights and emerging therapeutic approaches related to gastrointestinal and genitourinary microbiome in prostate cancer patients, especially focusing on available evidence and published trials on this topic.
科研通智能强力驱动
Strongly Powered by AbleSci AI